Category: Press Releases

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.

Read More

Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.

Read More

Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

Read More

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.

Read More

Genprex Begins Next Phase of Drug Branding Program

Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

Read More

Genprex Provides Update on Development of its Oncoprex Immunogene Therapy in Combination With Immunotherapy for Non-Small Cell Lung Cancer

Genprex today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria
Read More

Genprex Retains Addison Whitney for Drug Nomenclature Branding

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that it has taken a significant step toward commercialization of its lead drug candidate by retaining the services of
Read More